Skip to main content

Advertisement

Fig. 2 | BMC Cancer

Fig. 2

From: Post-therapy pathologic tumor volume predicts survival in gastric cancer patients who underwent neoadjuvant chemotherapy and gastrectomy

Fig. 2

Patient survival curves based on the 8th AJCC TNM staging system and our suggested ypTVNM categorization system a. Patients with ypTNM stage I, II and III did not show significant differences in survival (P = 0.476, 0.360, respectively). Only ypTNM stage IV demonstrated significant worse survival (P < 0.001). b. Significant differences in survival between patients with ypTvNM stage I, II, III and IV (P = 0.036, 0.001, < 0.001, respectively; Fig. 2b)

Back to article page